• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA Proposes Mandatory Electronic Report Submissions

February 13, 2018
American Veterinarian Editorial Staff

The FDA has proposed an amendment that would require certain animal drug reports to be submitted electronically.

The FDA announced today that it has proposed an amendment to its current regulations that would require all animal drug sponsors to submit certain adverse event and product manufacturing defect reports to the agency electronically.

The move to mandated electronic submissions is intended to improve the FDA’s systems for collecting and analyzing postmarketing safety reports by:

  • Expediting the review of safety reports and identification of emerging issues
  • Disseminating timely safety information to veterinarians and animal caretakers
  • Allowing better standardized safety reporting among regulatory agencies
  • Facilitating the international exchange of postmarketing safety information

“Although the FDA carefully evaluates new animal drugs before approval, there is the potential for new information to emerge after marketing, when the product is used in a much larger population and in settings different from the controlled studies required by the approval process,” the agency said in a press release announcing the proposal.

Advertisement

The proposed rule would officially replace the current system, which allows for either electronic or paper submissions. The FDA noted, however, that 99.7% of submitters already submit their reports electronically; the propsed rule is intended to make that figure 100%.

Under the new amendment, electronic submissions would be required for the following reports for approved new animal drugs:

  • 3-day alert reports that applicants submit directly to FDA’s Center for Veterinary Medicine
  • 15-day alert reports and follow-up reports
  • Product/manufacturing defect and adverse drug experience reports

The FDA will begin accepting public comments on the amendment on February 14. Comments can be submitted electronically by visiting regulations.gov and typing docket number FDA-2017-N-6381 into the search box. Alternatively, comments can be mailed to the agency:

Dockets Management Staff

HFA-305

Food and Drug Administration

5630 Fishers Lane, Room 1061

Rockville, MD 20852

Docket number FDA-2017-N-6381 should be written on each page of written comments. Comments will be accepted through April 30, 2018.


Advertisement

Latest News

Veterinary training to expand in Ontario with government investment

Pet Advocacy Network honors outstanding contributions to the pet care community

Traditional and holistic treatments for giardia

ASU trustees approve the creation of a new veterinary school

View More Latest News
Advertisement